Under the terms of the clinical study agreement, Chimeric will provide CHM 0201 study drug as
well as partial financial support for study. In addition to the modest financial support from
Chimeric, the study will be supported by grant funding from multiple funding sources including
Gateway for Cancer Research.
Sounds like a good deal on the financial side. The other current NK trial is full funded by other parties too, smart way of getting through the trials.
GLTA
Ann: Agreement with MD Anderson for Phase 1B CHM 0201 AML study, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |